Browse studies

Find your next paid study

27,306 recruiting studies available now

An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)

The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized …

Fibrodysplasia Ossificans Progressiva

Estimated

~$10 – $1,125

Actual pay is set by the research site.

IpsenNCT06089616

Phase 2

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition call…

Microvascular Inflammation

Estimated

~$75 – $3,000

Actual pay is set by the research site.

BiogenNCT07219043

Observational

Adjunctive Motivational Alcohol Intervention to Prevent Intimate Partner Violence

This is a study to provide much-needed experimental data on the efficacy of a brief alcohol Motivational Enhancement Therapy (MET) pre-group intervention for V…

Alcohol Use and Intimate Partner Violence

Estimated

~$10 – $675

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT05287711

Observational

Robotic Systems Evaluation for Peripheral Pulmonary Lesions: A Randomized Trial (RISE Trial)

This is an investigator-initiated cluster randomized control trial. The primary objective is to compare the diagnostic yield of two Food and Drug Administratio…

Lung; Node

Estimated

~$10 – $750

Actual pay is set by the research site.

Case Comprehensive Cancer CenterNCT07735611

Phase 3

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine)…

Ulcerative Colitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AbbVieNCT07071519

Phase 2

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, w…

Plaque Psoriasis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Oruka Therapeutics, Inc.NCT07449702

Phase 2

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with pl…

ObesityOverweight

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Eli Lilly and CompanyNCT07890376

Phase 1

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal…

Hepatic Impairment

Estimated

~$500 – $11,250

Actual pay is set by the research site.

AstraZenecaNCT07546760

Phase 2

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07154290

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gra…

Generalized Myasthenia Gravis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06463587

Phase 1

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07140016

Evaluation of the PACE/PACENET BHL Clinical Program

The SUpporting Seniors Receiving Treatment And INtervention (SUSTAIN) program is a telephone-based clinical service designed to help identify and manage behavi…

DepressionAnxietyPain, Chronic

Estimated

~$10 – $750

Actual pay is set by the research site.

University of PennsylvaniaNCT02463266